ONXX - ONYX Pharmaceuticals Inc

Your Recent Quotes: 0 | 0
Price Glossary Definition
34.36 -2.04
-5.60%
1/09/09 4:00
Open
35.95
Prev Close
36.40
Volume
1,153,893
52 Wk. Range
21.66- 54.84
Year-to-Date Performance Glossary Definition
UP 6.56%
Latest Dividend for ONXX
Dividend
N/A
Yield
0.00
Ex-Date
N/A
Price/Earnings Comparisons Glossary Definition
 
98.53
 
104.30
 
13.50
ONXX
Sect. Av.
S&P 500
Market Cap
2,001,040,100
Outstanding Shares
55,578,000
TheStreet Rating Glossary Definition
  • A
  • B
  • C
  • D
  • E
Buy ONXX Rating Report
Rating History for ONXX
Target Price (1Yr)
High
62.00
Revenue
206,830,000

Annual Dividend
Rate
0.00
Yield
0.00
Growth
12 Month
3 Year
CAGR
Revenue
-100.00
-1.00
0.00
Net Income
N/A
-0.27
0.00
EPS
N/A
-0.51
0.00

Stock Performance History
 
3 Month
1 Year
3 Year
Price Change
18.72
-32.78
26.21
Earnings Per Share($)

12/2005
 
 
 
-2.64
12/2006
 
 
 
-2.20
12/2007
 
 
 
-0.67

Earnings for ONXX
EBITDA
-84,929,000
Revenue
0
Outside Analyst Rating History

1/9/09
2
Buy
1/9/09
5
Hold
1/9/09
1
Sell

Jim Cramer Portfolio
Find out now if ONXX is in Jim's personal portfolio at Action Alerts PLUS.

Price & Volume

Latest ONXX Headlines
Here is a list of potential acquisition targets for the world's largest drugmaker.

8:03AM 01/08/09

The trading panel says investors are in for risky market conditions in 2009.

7:25PM 01/05/09

Market and economic turmoil and a new president cloud the forecast for the biotech sector, but investors can make some educated guesses.

12:57PM 12/23/08

China is experiencing huge growth in the pharma/healthcare sector - sparking interest from many global healthcare companies. Paul Boni, Chief Research Officer for Grail Research, breaks down the kind of growth he foresees for big pharmaceutical companies in the coming year thanks to the strong Chinese healthcare market.

06:59AM 12/19/08

Video
Accuray falls 16%.

5:16PM 11/07/08

Senior Columnist Adam Feuerstein re-examines the red flags in the Cell Genesys story so that when the same issues rear their ugly head in another biotech story investors will be better prepared.

10:00AM 10/20/08

Genentech is advancing T-DM1, which uses ImmunoGen technology, into a phase III study as a second-line treatment for Her-2 positive metastatic breast cancer.

11:37AM 10/17/08

Onyx Pharmaceuticals stock deserves to be higher, but the company first needs to better lay out its plans for growth.

11:37AM 10/10/08

The Mad About Options crew reviews Jim Cramer's recent bearish comments about Frontline Ltd. and offers options strategies for traders and investors. Also hear options ideas for Juniper Networks and Onyx Pharmaceuticals.

09:25AM 09/12/08

Video
Cramer says Lehman's CEO had chances to save his company but failed to take any action.

7:44PM 09/09/08

Understanding the Market

Our Experts' Take at RealMoney for ONYX Pharmaceuticals Inc
Traders are cycling back into 'slow motion' stocks and realizing that they oversold Wal-Mart.

12:39PM 01/09/09

Once again, sentiment is in the driver's seat.

8:58AM 01/09/09

More Experts' Takes on ONXX


Premium Stock Ideas
Is Cramer trading ONXX in his Action Alerts Plus Portfolio?